Mercury Biopharmaceutical Statistics
Total Valuation
Mercury Biopharmaceutical has a market cap or net worth of TWD 6.47 billion. The enterprise value is 6.24 billion.
Market Cap | 6.47B |
Enterprise Value | 6.24B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Mercury Biopharmaceutical has 414.50 million shares outstanding. The number of shares has increased by 3.20% in one year.
Shares Outstanding | 414.50M |
Shares Change (YoY) | +3.20% |
Shares Change (QoQ) | -0.08% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 0.04% |
Float | 390.21M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1,128.39 |
PB Ratio | 19.96 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -143.81 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -153.92 |
Financial Position
The company has a current ratio of 20.57, with a Debt / Equity ratio of 12.95.
Current Ratio | 20.57 |
Quick Ratio | 20.07 |
Debt / Equity | 12.95 |
Debt / EBITDA | n/a |
Debt / FCF | -1.03 |
Interest Coverage | -63.42 |
Financial Efficiency
Return on equity (ROE) is -11.79% and return on invested capital (ROIC) is -7.12%.
Return on Equity (ROE) | -11.79% |
Return on Assets (ROA) | -6.98% |
Return on Capital (ROIC) | -7.12% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.81% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -20.81% |
50-Day Moving Average | 15.50 |
200-Day Moving Average | 16.40 |
Relative Strength Index (RSI) | 50.64 |
Average Volume (20 Days) | 745,486 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mercury Biopharmaceutical had revenue of TWD 5.75 million and -43.41 million in losses. Loss per share was -0.10.
Revenue | 5.75M |
Gross Profit | 4.57M |
Operating Income | -46.80M |
Pretax Income | -43.39M |
Net Income | -43.41M |
EBITDA | -42.29M |
EBIT | -46.80M |
Loss Per Share | -0.10 |
Balance Sheet
The company has 264.89 million in cash and 41.95 million in debt, giving a net cash position of 222.94 million or 0.54 per share.
Cash & Cash Equivalents | 264.89M |
Total Debt | 41.95M |
Net Cash | 222.94M |
Net Cash Per Share | 0.54 |
Equity (Book Value) | 323.91M |
Book Value Per Share | 0.78 |
Working Capital | 262.12M |
Cash Flow
In the last 12 months, operating cash flow was -28.70 million and capital expenditures -11.86 million, giving a free cash flow of -40.56 million.
Operating Cash Flow | -28.70M |
Capital Expenditures | -11.86M |
Free Cash Flow | -40.56M |
FCF Per Share | -0.10 |
Margins
Gross Margin | 79.44% |
Operating Margin | -813.97% |
Pretax Margin | -754.57% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -705.41% |
Dividends & Yields
Mercury Biopharmaceutical does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.20% |
Shareholder Yield | -3.20% |
Earnings Yield | -0.67% |
FCF Yield | -0.63% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |